Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

European Stocks Higher; Marks & Spencer Soars with U.K. Retail Sector in Play

Published 08/24/2021, 04:14 AM
Updated 08/24/2021, 04:15 AM
© Reuters.

© Reuters.

By Peter Nurse 

Investing.com - European stock markets traded higher Tuesday, helped by stronger than expected German growth and the full U.S. approval of a Covid-19 vaccine.

At 4:15 AM ET (0815 GMT), the DAX in Germany traded 0.2% higher, the CAC 40 in France rose 0.1% and the U.K.’s FTSE 100 climbed 0.1%.

Economic data released Tuesday showed that the German economy grew more than expected in the second quarter. Gross domestic product climbed an adjusted 1.6% on the quarter, up from its previous estimate of 1.5%, helped by the easing of Covid-19 curbs.

That's a sharp rebound from the first quarter’s decline but gains have been limited given the Bundesbank's announcement on Monday that the country may miss full-year growth targets due to the delta variant. 

Also helping the sentiment in  European markets Tuesday were the strong gains on Wall Street overnight, with the tech-heavy Nasdaq Composite jumping 1.6% to a record closing high, after the U.S. Food and Drug Administration granted full approval to the Covid-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (DE:22UAy).

Investors are also keeping a wary eye on the situation in Afghanistan, with leaders from the Group of Seven industrial countries set to hold a virtual meeting later Tuesday to discuss the situation.

However, the main focus this week will be on the Federal Reserve’s Jackson Hole symposium that opens on Aug. 26, where further clues on the timeline for the U.S. central bank’s planning on asset tapering and interest rate hikes are expected.

In the U.K. retail sector, J Sainsbury (OTC:JSAIY) stock fell 1.7%, handing back some of Monday’s hefty gains on the back of a report that private equity firms were looking at this grocery chain. Marks & Spencer (OTC:MAKSY) stock rose 3.2% with this sector seemingly in play.  

Elsewhere, oil prices pushed higher, continuing Monday’s sharp rebound with the full approval of the Pfizer/BioNTech Covid-19 vaccine boosting hopes that greater vaccination levels will lead to a boost in fuel demand.

Investors now await U.S. crude oil supply data from the {{ecl-656||American Petroleum Institute, due later in the day, amid expectations for a hefty fall in inventories ahead of Labor Day weekend.

By 4:15 AM ET, U.S. crude futures traded 1.1% higher at $66.39 a barrel, while the Brent contract rose 1.2% to $69.19. Both contracts jumped more than 5% on Monday after recording their biggest week of losses in more than nine months last week.

Additionally, gold futures rose 0.2% to $1,803.15/oz, while EUR/USD traded 0.1% lower to 1.1737.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.